<DOC>
	<DOCNO>NCT00669955</DOCNO>
	<brief_summary>This study aim evaluate efficacy safety quadruple therapy ( bismuth , metronidazole , tetracycline omeprazole : OBMT ) v triple therapy ( amoxicillin , clarithromycin omeprazole : OAC ) H. Pylori eradication . It hypothesize quadruple therapy comparable efficacy triple therapy . Subjects confirm H. pylorus positive status randomize one treatment describe . At week 6 10 follow-up visit , urea breath test ( UBT ) perform confirm eradication .</brief_summary>
	<brief_title>Efficacy Safety Quadruple Therapy Eradication H. Pylori : A Comparison Triple Therapy</brief_title>
	<detailed_description>The study include three phase : screening , treatment follow-up . Screening : phase last maximum 30 day subject eligibility evaluate informed consent signature . Endoscopy Urea Breath test perform addition baseline routine evaluation . Treatment : Subjects assign OAC treat 7 day . Those assigned Pylera treat 10 day . A randomization visit take place Day 0 end-of-treatment visit take place day 8 14 . Follow-up : include two visit . approximately one two month post-treatment . Eradication H. Pylori confirm UBT , resistance evaluate case treatment failure . These subject undergo endoscopy .</detailed_description>
	<mesh_term>Helicobacter Infections</mesh_term>
	<mesh_term>Bismuth</mesh_term>
	<mesh_term>Bismuth tripotassium dicitrate</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Tetracycline</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<criteria>Positive H. Pylori status ; Presence upper gastrointestinal symptom ; Mental legal ability sign inform consent . Previous surgery GI tract ; Clinically significant impairment renal hepatic function ; Severe unstable cardiovascular , pulmonary endocrine disease ; Barrett 's oesophagus highgrade dysplasia ; Dysphagia vomit major symptom .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>H. Pylori</keyword>
	<keyword>Quadruple therapy</keyword>
	<keyword>Eradication rate</keyword>
	<keyword>Multinational trial</keyword>
	<keyword>Resistance antibiotic</keyword>
	<keyword>Subjects confirm Helicobacter Pylori infection</keyword>
</DOC>